Potential Treatment of Lysosomal Storage Disease through Modulation of the Mitochondrial—Lysosomal Axis
Lysosomal storage disease (LSD) is an inherited metabolic disorder caused by enzyme deficiency in lysosomes. Some treatments for LSD can slow progression, but there are no effective treatments to restore the pathological phenotype to normal levels. Lysosomes and mitochondria interact with each other...
Main Authors: | Myeong Uk Kuk, Yun Haeng Lee, Jae Won Kim, Su Young Hwang, Joon Tae Park, Sang Chul Park |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/2/420 |
Similar Items
-
Mitochondrial–Lysosomal Axis in Acetaminophen Hepatotoxicity
by: Anna Moles, et al.
Published: (2018-05-01) -
The rapidly evolving view of lysosomal storage diseases
by: Giancarlo Parenti, et al.
Published: (2021-01-01) -
A dual-labeling molecule for efficient drug discovery of mitochondrial-lysosomal interactions
by: Jinfang Wu, et al.
Published: (2024-08-01) -
Mitochondrial biogenesis is transcriptionally repressed in lysosomal lipid storage diseases
by: King Faisal Yambire, et al.
Published: (2019-02-01) -
Oncological Aspects of Lysosomal Storage Diseases
by: Agnieszka Ługowska
Published: (2024-10-01)